To conclude, accumulating evidence supports the validity of using evidence of immune activation, which can be measured with TILs or immune-related gene expression biomarkers, to stratify patients with early-stage ERBB2/HER2-positive breast cancer into different prognostic groups. This evidence concerns the gene ERBB2 and breast cancer.